Skip NavigationSkip to Content
Return Return to Search Results

Antineoplastic agents. 558. Ampelocissus sp cancer cell growth inhibitory constituents

  1. Author:
    Pettit, G. R.
    Mukku, V.
    Cragg, G.
    Herald, D. L.
    Knight, J. C.
    Herald, C. L.
    Chapuis, J. C.

  2. Author Address

    Pettit, George R.; Mukku, Venugopal J. R. V.; Herald, Delbert L.; Knight, John C.; Herald, Cherry L.; Chapuis, Jean-Charles] Arizona State Univ, Canc Res Inst, Tempe, AZ 85287 USA. [Pettit, George R.; Mukku, Venugopal J. R. V.; Herald, Delbert L.; Knight, John C.; Herald, Cherry L.; Chapuis, Jean-Charles] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA. [Cragg, Gordon] NCI, Frederick Canc Res & Dev Ctr, Div Canc Treatment & Diag, Dev Therapeut Program,Nat Prod Branch, Frederick, MD 21702 USA.
    1. Year: 2008
  2. Journal: Journal of Natural Products
    1. 71
    2. 1
    3. Pages: 130-133
  4. Type of Article: Article
  1. Abstract:

    An investigation of the Phillippine Ampelocissus sp. roots for cancer cell growth inhibitory components led to the isolation of a new acetogenin characterized as 22-epicalamistrin (1) employing primarily 2D NMR and high-resolution mass spectral analysis. Two other antineoplastic constituents proved to be the known acetogenin uvaribonin (2) and chalcone 3. Constituents 1-3 were all found to show significant cancer cell growth inhibitory activity against a panel of human cancer cell lines.

    See More

  1. Keywords:

External Sources

  1. PMID: 18177007

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel